- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02856139
Appearance of Far Peripheral Retina in Normal Eyes by Ultra-widefield Fluorescein Angiography
The Director of the Fundus Center of Zhongshan Ophthalmic Center
PURPOSE: To characterize the appearance of the far peripheral retina of normal eyes using ultra-widefield fluorescein angiography (UWFA).
DESIGN: Prospective observational case series. METHODS: This study enrolled normal eyes with best corrected visual acuity ≥ 20/20, refractive error < 3.00D, and without visible retinal pathologic changes under a slit lamp-based condensing lens. The far peripheral retina was detected by UWFA. Ciliary body thickness (CBT) at 3 mm (CBT1) and 2 mm (CBT2) posterior to the scleral spur was measured by ultrasound biomicroscopy.
Study Overview
Status
Conditions
Detailed Description
PURPOSE: To characterize the appearance of the far peripheral retina of normal eyes using ultra-widefield fluorescein angiography (UWFA).
DESIGN: Prospective observational case series. METHODS: This study enrolled normal eyes with best corrected visual acuity ≥ 20/20, refractive error < 3.00D, and without visible retinal pathologic changes under a slit lamp-based condensing lens. Demographic and clinical data such as age, sex, and reasons for undergoing FA were collected. The far peripheral retina was detected by UWFA. The fundal fields obtained using the Heidelberg ultra-widefield lens in a single shot and in montage images were compared with those acquired using the Heidelberg conventional 55° lens. The signs at the peripheral retina detected by UWFA were described and grouped. Ciliary body thickness (CBT) at 3 mm (CBT1) and 2 mm (CBT2) posterior to the scleral spur was measured by ultrasound biomicroscopy.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Zhongshan Ophthalmic Center, Sun Yat-sen University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- best corrected visual acuity ≥ 20/20
- refractive error < 3.00D
- without visible retinal pathologic changes under a slit lamp-based condensing lens
Exclusion Criteria:
- history of ocular surgery
- presence of ocular or systemic diseases
- opacity of refractive media, which interfered with the peripheral retina image quality
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
1 (MB- and VL-)
without mottled fluorescent band (MB) and vascular leakage (VL)
|
2 (MB+ and VL-)
with mottled fluorescent band (MB), without vascular leakage (VL)
|
3 (MB-/+ and VL+)
with or without mottled fluorescent band (MB), with vascular leakage (VL)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Ultra-widefield fluorescein angiography findings at the far peripheral retina of normal eyes
Time Frame: from November 2014 to January 2016
|
from November 2014 to January 2016
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Ciliary body thickness
Time Frame: from November 2014 to January 2016
|
from November 2014 to January 2016
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lin Lu, MD, PhD, Zhongshan Ophthalmic Center, Sun Yat-sen University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2016036
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Normal Eyes
-
OptovueCompletedNormal Eyes and Eyes With Ocular PathologiesUnited States
-
Alcon ResearchCompleted
-
University of HoustonNot yet recruitingNormal Healthy Eyes
-
Heidelberg Engineering GmbHTerminatedNormal Eyes | Retinal VascularUnited States
-
Heidelberg Engineering GmbHCompletedNormal Eyes | Retinal VascularUnited States
-
Heidelberg Engineering GmbHCompletedNormal Eyes | Retinal VascularUnited States
-
Topcon Medical Systems, Inc.CompletedSubjects Presenting With Normal EyesUnited States
-
OptovueCompletedNormal Eyes and Ocular PathologyUnited States